Development Pipeline

Our mission is to develop new canine therapeutics from advances in modern cancer medicine.

CaniVax is developing a portfolio of precision cancer medicines for dogs.

Our programmes include immune-enhancing cancer therapeutics and precision cancer vaccines targeting multiple canine cancers.

Our pipeline is supported by exclusive biological data, in-house AI capabilities, and a scalable proprietary development platform.

Development Stages

  1. 1 Microscope icon representing discovery and product design

    Discovery & Product Design

    Identify biological targets and design candidate product.

  2. 2 Immune cell icon representing preclinical validation

    Preclinical Validation

    Evaluate safety, biological activity and product performance.

  3. 3 Vial icon representing translational development

    Translational Development

    Optimise manufacturing, formulation and quality.

  4. 4 Veterinary clinic icon representing clinical development

    Clinical Development

    Clinical studies in dogs to assess safety & efficacy.

  5. 5 Approved certificate icon representing regulatory approval

    Regulatory Approval & Commercial Access

    Seek regulatory approval and expand access to canine patients.

CaniVax Pipeline

  • Complete
  • In progress
  • Planned
1Discovery & Product Design
2Preclinical Validation
3Translational Development
4Clinical Development
5Regulatory Approval & Commercial Access
Blue cancer cells icon CANIVIVE™ Multiple Cancers
Oral cancer drug. Enhances immune response against multiple cancers.
Green cancer cells icon CVX-001 Melanoma
Precision cancer vaccine designed against melanoma.
Red cancer cells icon CVX-002 Hemangiosarcoma
Precision cancer vaccine designed against hemangiosarcoma.
Purple cancer cells icon CVX-003 Mast Cell Tumours
Precision cancer vaccine designed against mast cell tumours.

Bringing Modern Cancer Science to Dogs

We believe dogs with cancer deserve to benefit from the same scientific progress transforming modern oncology.

Disclaimer: CaniVax programmes are investigational and not yet approved for use outside of clinical studies. Timelines, development plans, and programme descriptions reflect our current expectations, beliefs, and objectives, and are subject to change. Future development, regulatory progress, and commercial outcomes cannot be guaranteed.

Hands, vet and dog at clinic with consulting, care and stroke for health, development and growth with wellness. People, doctor and golden retriever pet with check, exam and help at animal hospital
Oxford

Scope and current status

CaniVax programmes are investigational and under active development. Initial efforts focus on a limited number of high-incidence canine cancers where tumour biology, clinical need, and immune targeting potential align.

Scientific and clinical updates will be shared as programmes reach defined milestones.

Register your interest below:

Name(Required)

Photo credit © Adrian Baughan - Oxford Dog Photography.